#1 Clinical Trials Search in Europe

Pralatrexate

Pralatrexate is an anti-cancer drug that has shown promise in treating various types of T-cell lymphomas, particularly in patients whose cancer has returned or not responded to other treatments. This article summarizes key findings from clinical trials investigating pralatrexate alone and in combination with other drugs for peripheral T-cell lymphoma (PTCL) and other T-cell malignancies.

Table of Contents

What is Pralatrexate?

Pralatrexate is a medication used in the treatment of certain types of cancer, particularly blood cancers. It is also known by its brand name Folotyn and has several other names in scientific literature, including PDX, 10-propargyl-10-deazaaminopterin, and (RS)-10-propargyl-10-deazaaminopterin[1][2][3]. This drug was developed to target specific cancer cells and interfere with their growth and spread.

How Pralatrexate Works

Pralatrexate belongs to a class of drugs called antifolates. It works by blocking the body’s ability to make folic acid, a protein that cancer cells need to grow and multiply[4]. By interfering with this process, pralatrexate can help slow down or stop the growth of cancer cells. It’s important to note that while the drug blocks folic acid production in cancer cells, patients are often given folic acid supplements to help reduce side effects in healthy cells.

Conditions Treated with Pralatrexate

Pralatrexate is primarily used to treat several types of blood cancers, including:

  • Peripheral T-cell Lymphoma (PTCL): This is a group of aggressive blood cancers that develop from mature T-cells, a type of white blood cell[1].
  • Cutaneous T-cell Lymphoma (CTCL): A type of cancer that affects the skin[4].
  • Non-Hodgkin’s Lymphoma: A broader category of blood cancers that includes PTCL[5].

Research is also being conducted to explore its effectiveness in treating other types of cancers, such as non-small cell lung cancer[6].

How Pralatrexate is Administered

Pralatrexate is typically given as an intravenous (IV) injection, which means it’s delivered directly into a vein. The most common dosing schedule is:

  • Once a week for 6 weeks, followed by 1 week of rest. This 7-week period is called a treatment cycle[1].
  • The injection is usually given over a short period, typically 3-5 minutes[3].
  • The dose is often based on body surface area, with a common starting dose being 30 mg/m²[1].

Patients receiving pralatrexate are also typically given vitamin B12 injections and daily folic acid supplements to help reduce side effects[3].

Clinical Trials and Research

Pralatrexate has been and continues to be the subject of numerous clinical trials. These studies aim to:

  • Determine the most effective dosage and schedule[2].
  • Evaluate its effectiveness in different types of cancers[6].
  • Assess its performance compared to or in combination with other cancer treatments[7].
  • Study its effects in specific patient populations, such as Asian patients with PTCL[1].

These trials help researchers better understand how pralatrexate can be used most effectively to treat various cancers.

Potential Side Effects

Like all medications, pralatrexate can cause side effects. Some of the most common side effects observed in clinical trials include:

  • Mucositis: Inflammation and ulceration of the mucous membranes lining the digestive tract[2].
  • Hematological toxicities: These include low white blood cell count (neutropenia), low platelet count (thrombocytopenia), and anemia[8].
  • Fatigue
  • Nausea and vomiting
  • Skin reactions

Your healthcare team will monitor you closely for these and other side effects and may adjust your treatment as needed.

Combination Therapies

Researchers are exploring the use of pralatrexate in combination with other cancer treatments to potentially enhance its effectiveness. Some combination therapies being studied include:

  • Pralatrexate with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), a common chemotherapy regimen[2].
  • Pralatrexate with romidepsin, another drug used to treat T-cell lymphomas[9].
  • Pralatrexate with pembrolizumab, an immunotherapy drug[10].
  • Pralatrexate with erlotinib, a drug used in some lung cancers[4].

These combination therapies are still being studied to determine their safety and effectiveness compared to single-drug treatments.

Aspect Details
Main Use Treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL)
Mechanism of Action Blocks folic acid production in cancer cells, inhibiting their growth
Administration Intravenous infusion, typically weekly for 6 weeks in a 7-week cycle
Common Dosage 30 mg/m² (may vary in different trials)
Response Rates 25-54% in various trials for PTCL
Common Side Effects Mucositis, low blood cell counts, nausea, fatigue
Combination Studies With romidepsin, pembrolizumab, erlotinib, and others
Key Outcomes Measured Overall response rate, progression-free survival, overall survival

FAQ

  • What is pralatrexate and how does it work? Pralatrexate is an anti-cancer drug that blocks the body's ability to make folic acid, a protein that may help cancer tissue develop and spread. It is designed to stop the growth of cancer cells by interfering with enzymes needed for cell growth.
  • What types of cancer is pralatrexate used to treat? Pralatrexate is primarily used to treat peripheral T-cell lymphoma (PTCL) and other T-cell lymphomas. It has shown effectiveness in patients whose cancer has relapsed or not responded to previous treatments.
  • How is pralatrexate typically administered? Pralatrexate is usually given intravenously (through a vein) over 3-5 minutes. The typical dosing schedule is once a week for 6 weeks, followed by 1 week without treatment, in a 7-week cycle. However, dosing may vary in different clinical trials.
  • What are some common side effects of pralatrexate? Common side effects may include mucositis (inflammation of the mouth and digestive tract), low blood cell counts (neutropenia, thrombocytopenia, anemia), nausea, fatigue, and skin reactions. Vitamin supplementation with B12 and folic acid is often given to help reduce side effects.
  • Is pralatrexate being studied in combination with other drugs? Yes, several clinical trials are investigating pralatrexate in combination with other drugs like romidepsin, pembrolizumab, and erlotinib to potentially improve effectiveness in treating T-cell lymphomas.

Ongoing Clinical Trials on Pralatrexate

  • Study on the Effectiveness and Safety of Belinostat and Pralatrexate with Drug Combination for Newly Diagnosed Peripheral T-Cell Lymphoma Patients

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Hungary Italy Poland Spain

Glossary

  • Peripheral T-cell lymphoma (PTCL): A group of aggressive blood cancers that develop from mature T-cells, a type of white blood cell important for immune function.
  • Relapsed/Refractory: Cancer that has returned after treatment (relapsed) or has not responded to initial treatment (refractory).
  • Response rate: The percentage of patients whose cancer shrinks or disappears after treatment.
  • Complete response (CR): The disappearance of all signs of cancer in response to treatment.
  • Partial response (PR): A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Overall survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Maximum tolerated dose (MTD): The highest dose of a drug that does not cause unacceptable side effects.
  • Dose-limiting toxicity (DLT): Side effects that are severe enough to prevent an increase in the dose of a drug being tested.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it is absorbed, distributed, metabolized, and excreted.
  • Intravenous (IV): Administration of a substance directly into a vein.
  • Mucositis: Inflammation and ulceration of the mucous membranes lining the digestive tract, a common side effect of some cancer treatments.
  • Neutropenia: An abnormally low count of neutrophils, a type of white blood cell important for fighting infections.
  • Thrombocytopenia: A condition in which there is a lower-than-normal number of platelets in the blood, which can lead to easy bruising and bleeding.

References

  1. https://clinicaltrials.gov/study/NCT03150602
  2. https://clinicaltrials.gov/study/NCT02594267
  3. https://clinicaltrials.gov/study/NCT00364923
  4. https://clinicaltrials.gov/study/NCT01532011
  5. https://clinicaltrials.gov/study/NCT00052442
  6. https://clinicaltrials.gov/study/NCT00004238
  7. https://clinicaltrials.gov/study/NCT01420679
  8. https://clinicaltrials.gov/study/NCT03356678
  9. https://clinicaltrials.gov/study/NCT03355768
  10. https://clinicaltrials.gov/study/NCT03598998